Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
71,92,248-0.83% Volume: 2,61,185 Cr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback